PRE-Pregnancy Weight Loss And the Reducing Effect on CHILDhood Overweight - Copenhagen

Exclusion Criteria

• •Diabetes mellitus (Type 1 or 2)
• •Previous or present eating disorder
• •Allergy towards ingredients in the very low calorie diet products
• •Severe heart, liver or kidney disease
• •Conception by in vitro fertilization (intrauterine insemination allowed)
• •≥4 consecutive spontaneous pregnancy loss (female)
• •Having tried to conceive or prior time to pregnancy of more than 12 months
• •Any medical condition or concomitant medication as judged by the medical responsible
• •Adherence to vegan diets or other diets interfering with the dietary guidelines in the study
• •Participation in other clinical trial
• •Engagement in elite sports or similar strenuous exercise ≥5 h/week
• •Blood donation or transfusion within the past month before baseline
• •Blood donation during the study
• •Inability or unwillingness to follow the study protocol and instructions given by the study personnel
• •Pregnancy registered between baseline visit and 4 weeks after the baseline visit (urinary analysis with dipstick)
• •Medical conditions as known by the participant:
• •Diabetes mellitus (type 1 and 2)
• •History or diagnosis of eating disorder (e.g. restrained eating, disinhibition, emotional eating)
• •Any significant medical condition as assessed by the investigator (e.g. dysregulated thyroid disease or reproductive diseases)
• •Any significant psychiatric disorder (i.e. schizophrenia, bipolar disease or depression) as assessed by the investigator
• •Severe chronic heart, liver and kidney disease
• •Polycystic ovary syndrome with irregular cycle
• •Amenorrhea
• •Severely reduced semen quality incl. azoospermia
• •Medication:
• •\- Current use of medication or use within the previous three months with a potential to affect body weight or pregnancy as judged by the investigator (e.g. systemic corticoids)
• •Personal/other:
• •Having tried to conceive or prior time to pregnancy of more than 12 months
• •Weight changes ± 5% three months prior to inclusion
• •Severe food allergies, food intolerances or dislike expected to interfere with the study, including allergy towards ingredients in the VLCD products
• •Engagement in elite sports or similar strenuous exercise ≥5 h/week
• •Blood donation or transfusion within the past month before baseline
• •Planned blood donation for other purpose than this study during participation
• •Alcohol abuse, as judged by the investigator, within the previous 12 months
• •Drug abuse, as judged by the investigator, within the previous 12 months
• •Psychological or behavioral problems which, in the judgement of the investigator, would lead to difficulty in complying with the study protocol
• •Participation in other clinical trials within the past three months or intention to do so during the study, which are judged by the investigator to affect the present study
• •Unable to consume the interventional product for religious reasons, swallowing disorders, other physiological reasons or any other reasons for not being able to follow the recommended diet
• •Inability or unwillingness to give written informed consent or communicate with study personnel
• •Inability or unwillingness to follow the study protocol and instructions given by the study personnel
• •Illiteracy or inadequate understanding of Danish or English language.
• •Any other condition that judged by the investigator may interfere with the adherence to the study protocol